eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.
To fight cancer, eTheRNA adopts multiple strategies including :
New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.
An innovative mRNA mix that mimics the action of oncolytic viruses to induce immunogenic death of tumour cells and renders the tumour more susceptible towards the anti-tumour T cell response
The different approaches can be combined with each other and other classes of treatment interventions.
To fight infectious diseases, eTheRNA is adapting its proprietary
TriMix technology to a product that can be administered intranasally or intramuscularly and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including SARS-CoV-2 (coronavirus).
[Preclinical, Clinical Phase I, Clinical Phase II, Clinical Phase III, Commercial]
IN naked mRNA vaccine for melanoma
Clinical: Phase I / II
LNP based E6-E7 vaccine
Oncolytic mRNA mix
Metastatic renal cell carcinoma
ID / autoimmune
© 2020 Etherna | Studio Hanswijk